Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer
Bunting PS, Goel V, Williams JI, Iscoe NA. CMAJ. 1999; 160(1):70-5.
Publications
Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer
Bunting PS, Chong N, Holowaty EJ, Goel V. Clin Biochem. 1998; 31(6):501-11.
Laboratory survey of prostate specific antigen testing in Ontario
Bunting PS, Miyazaki JH, Goel V. Clin Biochem. 1998; 31(1):47-9.
Prostate cancer screening in the midst of controversy: Canadian men’s knowledge, beliefs, utilization, and future intentions
Mercer SL, Goel V, Levy IG, Ashbury FD, Iverson DC, Iscoe NA. Can J Public Health. 1997; 88(5):327-32.
Socioeconomic status and cancer survival in Ontario
Mackillop WJ, Zhang-Salomons J, Groome PA, Paszat L, Holowaty E. J Clin Oncol. 1997; 15(4):1680-9.
The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario
Palda VA, Goel V, Sawka CA. Breast Cancer Res Treat. 1997; 43(1):33-41.
Physicians’ opinions about decision aids for patients considering systemic adjuvant therapy for axillary-node negative breast cancer
O'Connor AM, Llewellyn-Thomas HA, Sawka C, Pinfold SP, To T, Harrison DE. Patient Educ Couns. 1997; 30(2):143-53.
Patterns of initial management of node-negative breast cancer in two Canadian provinces
Goel V, Olivotto I, Hislop TG, Sawka C, Coldman A, Holowaty EJ. CMAJ. 1997; 156(1):25-35.
Development of an instrument to measure cancer screening knowledge, attitudes and behaviours
Kindree T, Ashbury FD, Goel V, Levy I, Lipskie T, Futcher R. Chronic Dis Can. 1997; 18(4):168-75.
Compliance with practice guidelines for node-negative breast cancer
Olivotto IA, Coldman AJ, Hislop TG, Trevisan CH, Kula J, Goel V, Sawka C. J Clin Oncol. 1997; 15(1):216-22.